Key result
Durable polymer EES demonstrate broad safety and efficacy as research targets 1-3 month DAPT.
Why the study?
Coronary percutaneous interventions have evolved through multiple stent iterations, with the durable polymer everolimus-eluting stent becoming the most commonly used device, prompting a review of its history, current status, and future perspectives.
This review highlights the established safety and efficacy of durable polymer everolimus-eluting stents across various clinical scenarios and notes the ongoing research interest in shortening dual antiplatelet therapy duration.
Affirms stent reliability for practice; leaves open optimal 1-3 month DAPT strategies pending randomized confirmation.
INTRODUCTION: Coronary percutaneous interventions have evolved from plain old balloon angioplasty (POBA) to stent implantation, which itself evolved from bare-metal stents (BMS) to the new biodegradable stents which try to restore endothelial function. Currently, the most commonly used stent is the everolimus-eluting stent. AREAS COVERED: This review will cover the current status of durable polymer everolimus-eluting stent, its history, and future perspectives. Nowadays, the everolimus-eluting stent is the most used device in the acute and chronic settings due to its safety and efficacy. EXPERT OPINION: Durable polymer everolimus-eluting stent, supported by much evidence, has demonstrated its efficacy and safety, not only in de novo artery lesions, but in multiples scenarios, such as the acute setting and diabetic population, becoming one of the most polyvalent stents available. Nowadays, research is focused on the reduction of antiplatelet treatment duration. Similar rates of stent thrombosis with short dual antiplatelet treatment regimens of 1 to 3 months compared to pronged treatment have been observed. However, specific studies should be performed to evaluate this possibility.
No takes yet. Share an insight, caveat, or question.
Rodríguez-Arias et al. (2020) conducted a review in Coronary artery disease. Durable polymer everolimus-eluting stent was evaluated. Durable polymer everolimus-eluting stents have demonstrated efficacy and safety across multiple scenarios, with current research focusing on reducing dual antiplatelet treatment duration to 1-3 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: